ActivBiotics Inc., of Lexington, Mass., received U.S. Patent Nos. 6,316,433, 6,566,354 and 6,362,169 covering certain dosage regimens and formulations related to its lead compound rifalazil.
Adherex Technologies Inc., of Ottawa, Ontario, said it was issued a patent related to methods for directly killing tumor cells with compounds based on the cadherin family of cell-adhesion molecules. The company said that disrupting cadherin-mediated tumor cell adhesion causes cancer cell death through apoptosis.
APT Pharmaceutical Inc., of Tucson, Ariz., received U.S. Patent No. 6,572,858 for its method of treating a variety of inflammatory illnesses by administering hydroxychloroquine directly to the site of inflammation. APT is developing aerosolized formulations of the widely used anti-inflammatory drug for asthma and rhinitis.
Atrix Laboratories Inc., of Fort Collins, Colo., was assigned U.S. Patent No. 6,565,874, which it said effectively extends patent protection for the prostate cancer products franchise, Eligard (leuprolide acetate for injectable suspension), to 2018. Sanofi-Synthelabo Inc., of New York, is the U.S. marketing partner for Eligard.
ChemGenex Therapeutics Inc., of Menlo Park, Calif., received a notice of allowance for its patent application titled "Naphthalimide Compositions and Uses Thereof." The patent will cover compositions and methods of use of its clinical-stage investigational agent, Quinamed (amonafide), to improve or chemopotentiate the anticancer effects of cisplatin.